Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a retrospective observational research study to describe the characteristics and real-world clinical outcomes of patients with chronic lymphocytic leukaemia receiving acalabrutinib in the United Kingdom (the EPIC study). Physicians treating chronic lymphocytic leukaemia patients with acalabrutinib, where the patients started treatment as part of the acalabrutinib Early Access Programme (EAP), will be invited to recruit patients. Clinical data will be extracted from the patients' clinical records in line with local laws. Data from this study will provide UK-specific real-world data on patients who were started on acalabrutinib as part of the UK acalabrutinib EAP.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjenci z białaczką limfocytową, którzy nigdy wcześniej nie byli leczeni
- •Rozpoczęli leczenie acalabrutinibem w ramach brytyjskiego programu wczesnego dostępu
- •Otrzymali pierwszą dawkę leku między 1 kwietnia 2020 a 1 kwietnia 2021
- •Wiek co najmniej 18 lat
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 130 Years
- Last updated (source)
- September 9, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (29)
Research Site
Aylesbury, United Kingdom
Research Site
Bath, United Kingdom
Research Site
Birmingham, United Kingdom
Research Site
Bournemouth, United Kingdom
Research Site
Cardiff, United Kingdom
Research Site
Cornwall, United Kingdom
Research Site
Dartford, United Kingdom
Research Site
Derby, United Kingdom
Research Site
Doncaster, United Kingdom
Research Site
Dorset, United Kingdom
Research Site
Eastbourne, United Kingdom
Research Site
Hull, United Kingdom
Research Site
Leicester, United Kingdom
Research Site
Lincoln, United Kingdom
Research Site
Liverpool, United Kingdom
Research Site
London, United Kingdom
Research Site
London, United Kingdom
Research Site
Mid Yorkshire, United Kingdom
Research Site
Middlesbrough, United Kingdom
Research Site
Newcastle, United Kingdom
Research Site
North Shields, United Kingdom
Research Site
Norwich, United Kingdom
Research Site
Nottingham, United Kingdom
Research Site
Oxford, United Kingdom
Research Site
Plymouth, United Kingdom
Research Site
Southampton, United Kingdom
Research Site
Stockton-on-Tees, United Kingdom
Research Site
Stoke-on-Trent, United Kingdom
Research Site
Wigan, United Kingdom
Trial contact
AstraZeneca Clinical Study Information Center
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/10/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.